Yesterday I came across a review by Anne Cherry and George Daley, published in Cell and available in open access. What i like about this review is that significance of reprogramming in creating of new disease models, highlighted by the authors.
This review includes a very good table summarizing all published “patient-specific iPS lines that have been differentiated into a disease-relevant cell type”. The authors discuss the value of iPS technology for disease modeling:
We predict that the value of patient-specific iPS cell-based disease modeling will be directly proportional to the disease heritability. What then are the prospects for modeling multifactorial diseases with genetic, environmental, and epigenetic components? The field is placing a bet that cells derived from patients who carry a highly penetrant genetic disease predisposition will provide insight into pathologic mechanisms of both the monogenic and multifactorial versions of the disorder.
Is this hope sound? It will be for sporadic forms of disease that have as their molecular underpinnings spontaneously arising mutations in genes that function in the same tissues as the familial forms.
This review is highly recommended! Full text.
Check out the whole special issue of Cell for free.